Clinical Trial Update: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase 1/Phase 2 trial evaluating a response-adapted regimen that includes ruxolitinib for hemophagocytic lymphohistiocytosis. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Hemophagocytic Lymphohistiocytosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING